These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32557844)

  • 1. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
    van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
    Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
    Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
    Puripat N; Loharamtaweethong K
    Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
    Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
    Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67.
    Kim JY; Jeong HS; Chung T; Kim M; Lee JH; Jung WH; Koo JS
    Oncotarget; 2017 Sep; 8(39):65064-65076. PubMed ID: 29029412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
    Finsterbusch K; Decker T; van Diest PJ; Focke CM
    Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.
    Gunia S; Kakies C; Erbersdobler A; Koch S; May M
    J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count.
    Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM
    Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
    Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
    PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
    Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.
    Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C
    Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
    Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
    Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
    Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
    Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
    Medani H; Elshiekh M; Naresh KN
    J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
    Tracht J; Zhang K; Peker D
    J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.